Skip to main content
Home Press Releases

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us

See what’s new.

https://otc.duke.edu/wp-content/uploads/2024/02/basking-biosciences-logo.png

Basking Biosciences Doses First Patients in Phase 2 Clinical Trial of Reversible Thrombolytic BB-031 for Acute Ischemic Stroke

Basking Biosciences, a start-up out of the lab of Professor Bruce Sullenger (Surgery, SOM), is developing a next-generation treatment for acute ischemic stroke.

Read More

https://otc.duke.edu/wp-content/uploads/2024/09/adaptin-bio-cover.png

Adaptin Bio Announces FDA Clearance of IND Application for APTN-101 in Glioblastoma

Adaptin Bio is a Duke start-up based around glioblastoma-related technologies developed in the lab of Dr. John Sampson (Neurosurgery, SOM).

Read More

https://otc.duke.edu/wp-content/uploads/2024/08/lindy-biosciences-logo.png

Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation

Lindy Biosciences is a Duke University start-up run by CEO Deborah Bitterfield (PhD MEMS, Pratt) based on technology developed in the lab of Professor Emeritus David Needham (MEMS, Pratt).

Read More

https://otc.duke.edu/wp-content/uploads/2024/08/David_Kasper_leaning.jpeg

Carpe, a Duke-founded Startup, Acquired by Topspin Consumer Partners

Founded by a Duke and UNC undergrad duo in 2015, Carpe creates antiperspirant solutions for consumers.

Read More

https://otc.duke.edu/wp-content/uploads/2024/08/mri-with-brain-tumor-magnetic-resonance-imaging-2023-11-27-05-35-17-utc-Large.jpeg

New therapy for glioma receives FDA approval, leveraging cancer research conducted at Johns Hopkins & Duke University

Drs. Darell Bigner and Hai Yan (Neurosurgery, SOM) and colleagues identified the genetic mutation targeted by this new drug. Dr. Katherine Peters (Neurosurgery, SOM) was lead investigator in the clinical trials.

Read More

https://otc.duke.edu/wp-content/uploads/2024/07/trudiagnostics-logo.png

The Kardashians Take Longevity Test that Reveals Biological Age in ‘The Kardashians’ Upcoming Season Finale

Kardashians use biological age algorithm technology developed by Professors Terrie Moffitt & Avshalom Caspi (Psychology & Neuroscience, SOM) and licensed to TruDiagnostics.

Read More

https://otc.duke.edu/wp-content/uploads/2024/06/amgen_logo.jpg

AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD)

Uplizna, an antibody therapy for immune diseases, is based on technology licensed from Duke University, developed by the late Dr. Thomas Tedder (Immunology, SOM) and colleagues.

Read More

https://otc.duke.edu/wp-content/uploads/2024/06/restor3d_sign.jpg

restor3d Announces Successful Closing of $70 Million Financing

restor3d is a Duke orthopedic medical device start-up spun out of the lab of Professor Ken Gall (MEMS, Pratt). DCP has participated in every round.

Read More

https://otc.duke.edu/wp-content/uploads/2024/05/davinci-merger-featured-image.png

Better Together: Elentra and DaVinci Education Combine to Drive Transformation in Healthcare Education

DaVinci Education is a Duke University start-up, spun out around technology developed by David Wiener, Colleen Grochowski, and Vice Dean Dr. Edward Buckley (Ophthalmology, SOM).

Read More

1 2 3 30